Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Complement component C9 in Graves' disease.

D A Oleesky1, S Ratanachaiyavong, M Ludgate

  • 1Department of Medical Biochemistry, University Hospital of Wales, UK.

Clinical Endocrinology
|December 1, 1986
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Importance of cannulated prolactin test in the definition of hyperprolactinaemia.

Pituitary·2014
Same author

Phaeochromocytoma [corrected] crisis.

Clinical endocrinology·2013
Same author

An observational study of cognitive function in patients with irritable bowel syndrome and inflammatory bowel disease.

Neurogastroenterology and motility·2013
Same author

Selectivity mechanism of the mechanosensitive channel MscS revealed by probing channel subconducting states.

Nature communications·2013
Same author

Symptoms of irritable bowel syndrome in patients with inflammatory bowel disease: examining the role of sub-clinical inflammation and the impact on clinical assessment of disease activity.

Alimentary pharmacology & therapeutics·2013
Same author

Enzymatic activity of albumin shown by coelenterazine chemiluminescence.

Luminescence : the journal of biological and chemical luminescence·2012
Same journal

Supraphysiological Glucocorticoid Doses and Pitfalls of Annual Biomarker Monitoring in Adults With CAH.

Clinical endocrinology·2026
Same journal

Subacute Thyroiditis in Denmark: A Nationwide Study of 1763 Cases.

Clinical endocrinology·2026
Same journal

Pubertal Dynamics of Sertoli and Leydig Cell Dysfunction in Klinefelter Syndrome.

Clinical endocrinology·2026
Same journal

Regarding Non-Classical Presentations of Rare Hereditary Hypoparathyroidism: A Case Series of CASR, GNA11, and GATA3 Mutations in Parathyroidology.

Clinical endocrinology·2026
Same journal

Dual Metabolic Burden of Polyendocrine Metabolic Ovarian Syndrome (PMOS) and Gestational Diabetes in Pregnancy: Impact on Neonatal Anthropometry: Insights From the Born in Bradford Cohort.

Clinical endocrinology·2026
Same journal

Preoperative CALLY Index for Identifying Atypical Parathyroid Tumors.

Clinical endocrinology·2026
See all related articles

Elevated levels of complement component 9 (C9) were found in Graves' disease patients, suggesting its involvement in the condition. C9 levels decreased with antithyroid drug treatment, further supporting its role in Graves' disease pathogenesis.

Area of Science:

  • Immunology
  • Endocrinology

Background:

  • Complement component 9 (C9) is crucial for membrane attack complex formation and acts as an acute phase protein.
  • The role of C9 in Graves' disease, an autoimmune thyroid disorder, remains unclear.

Purpose of the Study:

  • To investigate the potential involvement of C9 in the pathogenesis of Graves' disease.
  • To measure plasma C9 concentrations in patients with hyperthyroid Graves' disease and compare them to normal subjects.

Main Methods:

  • Plasma C9 concentrations were measured using an automated two-site immunoradiometric assay with monoclonal antibodies.
  • Immunohistochemical staining and radiolabelled antibody binding were used to assess C9 localization in thyroid tissue.

Main Results:

Related Experiment Videos

  • Plasma C9 concentrations were significantly higher in hyperthyroid Graves' disease patients compared to normal individuals.
  • C9 levels decreased significantly after treatment with antithyroid drugs but not after radioactive iodine therapy.
  • Monoclonal antibodies to C9 bound to thyroid follicular basement membranes in Graves' disease tissue, but not in normal tissue.

    • Conclusions:

    • C9, and by extension the membrane attack complex, may play a role in the pathogenesis of Graves' disease.
    • The findings suggest C9 as a potential biomarker or therapeutic target in Graves' disease management.